|
C22ORF30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.55239999743984E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.81729999948877E-07 |
| Normal-vs-Stage2 |
3.140500E-03 |
| Normal-vs-Stage3 |
1.03049999977678E-07 |
| Normal-vs-Stage4 |
5.06599995286905E-09 |
| Stage1-vs-Stage2 |
5.298800E-01 |
| Stage1-vs-Stage3 |
1.434850E-01 |
| Stage1-vs-Stage4 |
9.237700E-03 |
| Stage2-vs-Stage3 |
1.329770E-01 |
| Stage2-vs-Stage4 |
1.398220E-02 |
| Stage3-vs-Stage4 |
1.668370E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.58069999814481E-08 |
| Normal-vs-AfricanAmerican |
9.921200E-03 |
| Normal-vs-Asian |
9.6257000000044E-05 |
| Caucasian-vs-AfricanAmerican |
4.406200E-01 |
| Caucasian-vs-Asian |
9.809200E-01 |
| AfricanAmerican-vs-Asian |
5.000800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.31980000004506E-07 |
| Normal-vs-Female |
3.19570000462122E-08 |
| Male-vs-Female |
5.769400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.40660000000648E-06 |
| Normal-vs-Age(41-60Yrs) |
3.33070000468894E-08 |
| Normal-vs-Age(61-80Yrs) |
8.60799999946593E-07 |
| Normal-vs-Age(81-100Yrs) |
1.380240E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.073200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.843000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.170000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.716800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.459800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.613000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.786100E-02 |
| Classical-VS-Follicular |
2.783700E-02 |
| Classical-VS-Other |
1.295420E-01 |
| Classical-VS-Normal |
1.58719999998613E-06 |
| Tall-VS-Follicular |
8.221800E-01 |
| Tall-VS-Other |
5.383400E-01 |
| Tall-VS-Normal |
2.35639999999204E-05 |
| Follicular-VS-Other |
4.840000E-01 |
| Follicular-VS-Normal |
2.88339999987564E-07 |
| Other-VS-Normal |
3.602600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.82340000051984E-07 |
| Normal-vs-N1 |
4.53130000188651E-08 |
| N0-vs-N1 |
6.406100E-02 |
|
|
